Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atebimetinib - Immuneering

Next Previous
Drug Profile

Atebimetinib - Immuneering

Alternative Names: IMM-1-104

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immuneering
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Aug 2025 Immuneering Corporation entered into a clinical supply agreement with Eli Lilly and Company for olomorasib
  • 25 Aug 2025 Immuneering plans a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line or greater therapy, Metastatic disease)
  • 13 Aug 2025 Immuneering submits end of phase 2 meeting request to US FDA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top